Table 2.
ADE | Phase I (n = 34) | Phase II (n = 27) |
---|---|---|
Dosing Schedule | 2x(B140M125T125) + A500 + E20 bid x10d | 3x(B140M125T125) + A500 + E20 bid x10d |
Eradication success (ITT) | 20/34 (59%) | 17/27 (63%) |
Eradication success (PP) | 20/30 (67%) | 17/26 (65%) |
Any ADE | 10 (29%) | 9 (33%) |
ADE: adverse drug events.